Cargando…
A targeted approach to reducing rates of discontinuation and dose reduction in patients receiving sorafenib or regorafenib
Background: Sorafenib and regorafenib are oral multikinase inhibitors used to treat some cancers, but adverse events for both drugs are common and often cause patients to discontinue therapy or reduce their dose within several months of initiating therapy. Pharmacists have the potential to prevent d...
Autores principales: | Nix, Ryan, Looney, Brooke, Lamb, Carson, Peter, Megan, Zuckerman, Autumn |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6764342/ http://dx.doi.org/10.1080/21556660.2019.1658310 |
Ejemplares similares
-
Long-Term Regression after Discontinuation of Regorafenib Administered for Sorafenib-Refractory Hepatocellular Carcinoma
por: Bae, Heewon, et al.
Publicado: (2023) -
Medial Patellofemoral Ligament Reconstruction for Patellar Dislocation: A Systematic Review
por: Mackay, Nicola D., et al.
Publicado: (2014) -
Mechanistic Modeling of the Effects of Acidosis on Thrombin Generation
por: Mitrophanov, Alexander Y., et al.
Publicado: (2015) -
Patellar Tendon–Trochlear Groove Angle Measurement: A New Method for Patellofemoral Rotational Analyses
por: Hinckel, Betina B., et al.
Publicado: (2015) -
Operative Management of Patellar Instability in the United States: An Evaluation of National Practice Patterns, Surgical Trends, and Complications
por: Arshi, Armin, et al.
Publicado: (2016)